- 1 Predictive models for secondary epilepsy within 1 year in patients with acute ischemic
- 2 stroke: a multicenter retrospective study
- 3 Jinxin Liu^{1,2†}, Haoyue He^{1,3†}, Yanglingxi Wang¹, Jun Du⁷, Kaixin Liang⁸, Jun Xue⁹, Yidan
- 4 Liang¹, Peng Chen¹, Shanshan Tian⁶, Yongbing Deng^{1,4,5,}
- 5 1 Department of Neurosurgery, Chongqing Emergency Medical Center, Chongqing
- 6 University Central Hospital, Chongqing, China
- 7 2 School of Medicine, Chongqing University, Chongqing, China
- 8 3 Bioengineering College of Chongqing University, Chongqing, China
- 9 4 Chongqing Key Laboratory of Emergency Medicine
- 10 5 Jinfeng Laboratory, Chongqing, China
- 11 6 Department of Prehospital Emergency, Chongqing University Central Hospital,
- 12 Chongqing Emergency Medical Center, Chongqing, China
- 13 7 Department of Neurosurgery, Chongqing University Qianjiang Hospital, Chongqing,
- 14 China
- 8 Department of Neurosurgery, Yubei District Hospital of Traditional Chinese Medicine,Chongqing, China
- 17 9 Department of Neurosurgery, Bishan hospital of Chongqing Medical University,
- 18 Chongqing, China
- 19 8 Chongqing Key Laboratory of Emergency Medicine
- 20
- ²¹ [†]These authors have contributed equally to this work and share first authorship.
- 22
- 23 Corresponding author: Yongbing Deng Email: dyb0913@cqu.edu.cn
- 24
 Shanshan Tian Email: 710836163@qq.com

 25
 26

 27
 28

 29
 30

 31
 32

- 33
- 34
- 35
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44

45

46

47 Author Contributions

48 JL and HH are both first writer who analysed the data by python and wrote 49 the first draft of the manuscript.YD and TS are both corresponding author 50 who wrote part of the draft and designed the original research. Chongging 51 University Central Hospital, Chongqing University Qianjiang Hospital, Yubei 52 District hospital and Bishan hospital of Chongqing Medical University 53 provided the database of all cases of the patients. The others collected 54 data and wrote sections of the manuscript. All authors took part in the 55 research and contributed to manuscript revision, read, and approved the 56 submitted version.

57

58 Data availability statement

59 The codes, models, analysis results can be provided for researchers if needed 60 by the corresponding author.

61

62 Acknowledgements

63 The authors would like to thank the colleagues in the information and 64 imaging departments for their hard work contributing to the final research 65 results.

66 Ethics approval statement

67 We confirm that we have read the Journal's position on issues involved in 68 ethical publication and affirm that this report is consistent with those 69 guidelines.

70 Funding statement

71 The research is funded by Based on artificial intelligence and multiple 72 omics technology set up a system of auxiliary cardiovascular disease 73 diagnosis and treatment(2023CDJYGRH-ZD06); by Emergency medicine Key 74 laboratory of Chongqing Joint Fund for Talent Innovation and development 75 (2024RCCX10), by Brain-like intelligence research Key laboratory of 76 chongqing Education Commission(BIR2019004)

77 Conflict of interests

78 The authors have no relevant conflicts of interest to disclose.

79

- 80 Patient consent statement
- 81 This study was a retrospective study and only deidentified patient data 82 were collected, exempting the need for patient informed consent rights.
- 83
- 84 **Permission to reproduce material from other sources**
- 85 There are no reproduce material from other sources.

86

- 87 Clinical trial registration
- 88 The trail number is RS202406.

89

90 Abstract

91 Objective:

Post-stroke epilepsy (PSE) is a significant complication that has a negative impact
 on the prognosis and quality of life of ischemic stroke patients. We collected medical
 records from 4 hospitals in Chongqing and created an interpretable machine learning
 model for prediction.

96 Methods:

97 We collected medical records, imaging reports, and laboratory tests from 21459 patients with a diagnosis of ischemic stroke. We conducted traditional univariable and 98 99 multivariable statistics analyses to compare and identify important features. Then the 100 data was divided into a 70% training set and a 30% testing set. We employed the Synthetic Minority Oversampling Technique combined with Edited Nearest Neighbors 101 102 method to resample an imbalanced dataset in the training set. Nine commonly used 103 methods were used to build machine learning models, and relevant prediction metrics 104 were compared to select the best-performing model. Finally, we used SHAP(SHapley) Additive exPlanations) for model interpretability analysis, assessing the contribution 105 and clinical significance of different features to the prediction. 106

107 Results:

108 In the traditional regression analysis, complications such as hydrocephalus, cerebral hernia, uremia, deep vein thrombosis; significant brain regions included the 109 involvement of the cortical regions including frontal lobe, parietal lobe, occipital lobe, 110 temporal lobe, subcortical region of basal ganglia, thalamus and so on contributed to 111 PSE. General features such as age, gender, and the National Institutes of Health Stroke 112 Scale score, as well as laboratory indicators including WBC count, D-dimer, lactate, 113 114 HbA1c and so on were associated with a higher likelihood of PSE. Patients with conditions such as fatty liver, coronary heart disease, hyperlipidemia, and low HDL had 115 a higher likelihood of developing PSE. The machine learning models, particularly tree 116 models such as Random Forest, XGBoost, and LightGBM, demonstrated good predictive 117 118 performance with an AUC of 0.99.

119 Conclusion:

120 The model built on a large dataset can effectively predict the likelihood of PSE, with 121 tree-based models performing the best. The NIHSS score, WBC count and D-dimer were 122 found to have the greatest impact.

123

124 Introduction

125 Stroke is the second leading cause of death worldwide, with an annual mortality rate 126 of approximately 5.5 million, and also the leading cause of disability globally, accounting

for 50% of cases [1]. Generally, ischemic stroke accounts for the majority, about 80% of 127 stroke cases [2][3]. Post-stroke epilepsy (PSE) is a significant complication, with studies 128 indicating that as many as 3-30% of stroke patients develop epilepsy, which has a 129 130 negative impact on patients' prognosis and quality of life [4]. It can exacerbate cognitive, psychiatric, and physical impairments caused by cerebrovascular disease and 131 comorbidities [5]. Furthermore, the highest incidence of PSE occurs within the first year 132 after acute stroke, accounting for about half of the cases [2]. Therefore, early prediction 133 134 and intervention for PSE, especially ischemic ones, are crucial.

135 Currently, most studies utilize clinical data to establish statistical models, survival analysis and cox regression [2][6], and multiple linear regression [7] to construct simple 136 models for the prediction of PSE. Last year, Lin et al. developed a model based on 137 radiomics that outperformed the conventional clinical model in predicting PSE related to 138 intracerebral hemorrhage (ICH). They suggested that a combined radiomics-clinical 139 140 model could better assist clinicians in assessing the individual risk of PSE after the first 141 occurrence of ICH and facilitate early diagnosis and treatment of PSE [8]. However, subsequent studies have raised doubts regarding the application of radiomics, suggesting 142 the need for further research [9]. Overall, there is still a relative scarcity of research on 143 144 PSE prediction, with most studies focusing on the analysis of specific or certain risk factors [10][11][8][12] constructing simple models and hardly proposed or established a 145 more comprehensive and scientifically accurate prediction model. 146

147 Machine learning has emerged as a promising approach in recent years for constructing medical models, as it excels in handling large volumes of data and complex 148 information, and has been increasingly applied in neuroscience and clinical prediction 149 [13][14][15]. Previous studies have utilized machine learning for related research on 150 post-stroke cognitive impairments [16], stroke and myocardial infarction risk prediction 151 models in large artery vasculitis patients [14], post-stroke depression prediction models 152 based on liver function test indicators [17], and prediction of hematoma expansion in 153 traumatic brain injury (TBI) [18]. Models constructed using machine learning algorithms 154 can automatically handle linear or complex nonlinear relationships between different 155 variables and provide insights into the contribution of different features to the prediction 156 target, which is challenging for traditional statistical models. However, machine learning 157 methods require a substantial amount of data and are prone to overfitting when trained on 158 small sample data. The more valid and high-quality data input, the better machine 159 160 learning algorithms can capture the underlying patterns between the data, thereby 161 achieving more accurate predictions.

162 This study try to select important risk factors from mutiple fearures extracted from 163 the clinical records and examination data of ischemic stroke patients and subsequently 164 develops a prediction model for PSE using machine learning methods. By utilizing 165 relevant early admission features of ischemic stroke patients, we aim to automatically 166 predict the probability of PSE occurrence and further guide clinical decision-making and 167 nursing care.

168 Research content and method

169 **Research patients**

170 This study retrospectively included all stroke patients admitted to the Chongqing Emergency Center between June 2017 and June 2022 for the development of the 171 prediction model. Subsequently, patient data from three external validation centers, 172 namely, Qianjiang Central Hospital, Bishan District People's Hospital, and Yubei District 173 Traditional Chinese Medicine Hospital, were collected between July 2022 and July 2023 174 for external validation and evaluation of the model. The external validation cohort 175 176 focused more on collecting positive cases to examine the model's ability to identify 177 positive samples.

Inclusion criteria: (1) Age between 18 and 90 years at admission; (2) Diagnosed
with acute ischemic stroke and hospitalized for treatment.

Exclusion criteria: (1) Patients with a history of stroke or transient ischemic attack (TIA); (2) Patients with a history of other conditions such as traumatic brain injury, intracranial tumors, or cerebral vascular malformations that may cause epilepsy; (3) Patients with a history of epilepsy or who have received antiseizure medications for the prevention of seizures or for other diseases (such as migraine or psychiatric disorders); (4) Patients who died within 72 hours after stroke onset.

This study collected de-identified data from relevant patients for the construction of
a multi-modal database for stroke patients. The study protocol was approved by the
Ethics Committees of Chongqing University Center Hospital, Chongqing University
Qianjiang Central Hospital, Bishan District People's Hospital, and Yubei Traditional
Chinese Medicine Hospital.

The procedure of selection is in figure1. Total there are 42079 records from the 191 stroke database, 24733 patients were diagonosed as ischemic stroke or lacular stoke with 192 new onset. Then we excluded hemorrage stroke(4565), history of stroke(2154), 193 TIA(3570), unclear cause stroke(561) and records who missed important data(6496). 194 195 Then we excluded patients whose seizure might be attributed to other potential causes (brain tumor, intracranial vascular malformation, traumatic brain injury,etc)(865). Then 196 we exclude patient who had a seizure history(152) or died in hospital (1444). Then we 197 excluded patients who were lost to follow-up (had no outpatient records and cant contact 198 199 by phone)or died within 3 months of the stroke incident(813). Finally 21459 cases are involved in this research. 200

201

202 Data collection

We extracted all records and other relevant data from the database of the
hospitals. Under the structure of PostgreSQL we coded Structured Query
Language to manage different data as follows:

(1) General information: gender, age, NIHSS(the National Institutes of Health
 Stroke Scale) score at admission;

(2) (2) Comorbidities and complications: uremia, DVT(previous deep vein
thrombosis), diabetes mellitus, hypertension, coronary atherosclerosis, atrial fibrillation,
cerebral hernia, hydrocephalus, hypoproteinemia, hyperuricemia, hyperlipidemia, internal
carotid stenosis, common carotid stenosis, etc.

212 (3) According to CT or MRI records, the patient's cortical lobes and subcortical involvement were counted: frontal lobe \ parietal lobe \ temporal lobe \ occipital lobe \ 213 insular lobe \ basal ganglia \ internal capsule \ brain stem \ cerebellum \ periventricular \ 214 215 centrum semiovale \ thalamus involvement. In addition, the extent of cortical involvement (frontal lobe, parietal lobe, temporal lobe, occipital lobe and insular lobe 216 each accumulated 1 point) and the extent of subcortical involvement (basal ganglia, 217 218 internal capsule, brain stem, periventricular, thalamus and cerebellum any accumulated 1 219 point) were summarized.

(4) According to CTA, MRA or DSA records, the patient's vascular stenosis or
 occlusion was counted: ACA(anterior cerebral artery) \ MCA(middle cerebral artery) \
 PCA(posterior cerebral artery) \ VA(vertebral artery) \ BA(basilar artery)

(5) Important laboratory indicators: Blood lipids (TG(Triglyceride), HDL(High 223 Density Lipoprotein Cholesterol), LDL(Low Density Lipoprotein Cholesterol)), liver 224 function (ALT(Alanine Transaminase), AST(Aspartate Aminotransferase), Bilirubin, 225 Albumin), renal function (Urea, BUA(Blood Uric Acid), Creatinine), blood gas (Lactate, 226 227 Anion Gap, TCO2(Total Carbon Dioxide)), coagulation related indicators (INR(International Normalized Ratio), PT(Prothrombin Time), APTT(Activated Partial 228 Thromboplastin Time), TT(Thrombin Time), D-Dimer, Fibrinogen) and myocardial 229 230 enzymes (CK(Creatine Kinase), CK-MB(Creatine Kinase Isoenzyme), LDH(Lactate Dehydrogenase), IMA(Ischemic Modified Albumin), HBDH(α -Hydroxybutyrate 231 232 Dehydrogenase)).

233

234 Data processing and model building

(Processing of missing data) We counted the values of all laboratory indicators for 235 236 the first time after stroke admission(everyone who was admitted because of stroke would 237 perform blood routine, liver and kidney function and so on), excluded indicators with missing values of more than 10%, and filled the data of the remaining indicators with 238 missing values by random forest algorithm using the default parameter. First, we go 239 through all the features, starting with the one with the least missing (since the least 240 accurate information is needed to fill in the feature with the least missing). When filling 241 in a feature, replace the missing value of the other feature with 0. Each time a regression 242 prediction is completed, the predicted value is placed in the original feature matrix and 243 the next feature is filled in. After going through all the features, the data is complete. 244

- 245 (Distribution of characteristics) Univariate analysis was used to examine the
- 246 distribution of characteristics between the PSE negative group and the positive group.
- 247 The data were then divided into a training set and a test set by .
- 248 (Processing of unbalanced data) Considering the low incidence of PSE and the small
- 249 proportion of positive patients, the positive data of the training set were augmented by
- 250 Synthetic Minority Over-sampling Technique combined with Edited Nearest Neighbors
- 251 by using default parameter of SMOTEENN method from imblearn python package and
- set random seed at 42 for repetition.

(Processing of categorical data) For categorical data, the one-hot method is used for
 transformation. The LASSO method was then used in the training set to screen the
 important features.

(Model building) We first used LASSO regression to select the 20 most important 256 features. Next, we employed 9 common machine learning methods, including Naive 257 Bayes, Logistic Regression, Decision Tree, Random Forest, Gradient Boosting, Multi-258 Layer Perceptron, XGBoost, LightGBM, and K-Nearest Neighbors. We then optimized 259 the hyperparameters of each model through grid search to improve their performance. To 260 evaluate the models, we calculated metrics such as accuracy, sensitivity, specificity, F1-261 262 score, positive predictive value, and negative predictive value. We also plotted the ROC curve, calibration curve, and decision curve. Additionally, we used an independent 263 264 external validation dataset to assess the generalization performance of the selected model. 265 Finally, we leveraged the SHAP algorithm to perform an interpretable analysis of the best-performing model, investigating the contribution of each feature to the model's 266 predictions and their clinical significance. Through this series of model building. 267 268 optimization, and analysis, we developed a machine learning model with good predictive performance and interpretability, providing valuable support for clinical decision-making. 269

270

271 Statistical approach

272 PostgreSQL v15 (http://www.postgresql.org/) was used to search and extract the
273 data from the local database.

The open-source statistical package "Scipy.stats" in Python was used for statistical analysis. The details of the univariate significance analysis for each feature are as follows:

First, the Shapiro-Wilk test was used to check the normality of the distribution for each feature. For features that did not follow a normal distribution, the Mann-Whitney U test was used to assess their significance with respect to the target variable.

For features that exhibited a normal distribution, the Levene test was employed to assess the homogeneity of variances. Features with homogeneous variances were analyzed using the Student's t-test to determine their significance with respect to the target variable, while features with heterogeneous variances were analyzed using the Welch's t-test.

The confidence intervals for the AUC values and Brier scores were obtained by performing 1000 bootstrap resampling iterations on the corresponding datasets. The binary classification thresholds for the predicted probabilities generated by all models were established using the maximum Youden index derived from the training cohort.

Throughout the study, a two-tailed p-value less than 0.05 was considered statistically significant.

All the codes were uploaded at https://github.com/conanan/lasso-ml.

291 **Results**

292 Filling of missing data

These features had missing values that were filled using a Random Forest (RF)
model, addressing the missing data one feature at a time: Plt, WBC, RBC, HbA1c, CRP,
TG, LDL, HDL, AST, ALT, Bilirubin, Albumin, Urea, Creatinine, BUA, PT, APTT, TT,
INR, D-dimer, Fibrinogen, CK, CK-MB, LDH, HBDH, IMA, Lactate, Anion_gap, TCO2,
NIHSS.

298 Characteristics of study participants

A total of 21459 patients were included in this study, of which 15021 patients were included in the training set, and the incidence of PSE was 4.3%. The test set contained 6438 patients with a PSE incidence of 4.3%. The external validation cohort consisted of 536 patients at three hospitals. Statistical details of the clinical characteristics of the patients are provided in the table1.

304 Statistical analysis showed that the patients who had higher possibility of PSE were with complications of uremia, history of DVT, atrial fibrillation, hyperuricemia, cerebral 305 hernia and hydrocephalus. The involved locations of frontal lobe, parietal lobe, occipital 306 lobe, temporal lobe, cortex, subcortex, basal ganglia and hypothalamus. The general 307 characteristics included age, gender, nihss score; Laboratory indicators included wbc 308 309 count, hba1c, crp, tg, ast, alt, bilirubin, urea, bua, aptt, tt, d dimer, ck, ckmb, ldh, hbdh, ima, lactate, and anion gap. Besides, the p values of fatty liver, coronary heart disease, 310 311 hyperlipidemia, and hdl were significant, and patients with negative or low values of 312 these indicators had a high risk of secondary disease. The statistics analysis result, the uni and multi regression analysis result table is in table1, table 2 and table 3. 313

314 Performance of machine learning models

The relevant indicators of the machine learning model are shown in table4, and the 315 316 ROC curves, calibration curve and DCA are shown in figure3. It can be found that the over all models the AUC of tree models such as RF, XGboost and lightGBM are better 317 than other models, and the PPV value of random forest is the highest, reaching 0.864, 318 319 which is the most important function of our models. Complex machine learning algorithms were superior to traditional logistic regression. The Brier score of the 320 321 calibration curve reached 0.006, and the DCA also showed good clinical decision-making 322 benefits, which had good practical value. In the external validation cohort, we use the RF to predict. The Sensitivity was 0.91, the PPV was 0.95, demonstrate a good predictive 323 ability of the model. 324

325 Analysis of SHAP risk factors

- 326 The analysis in Figure 4 shows the SHAP (Shapley Additive Explanations) values,
- 327 individual decision attempts, and overall decision curves. Among the general
- 328 characteristics, females had a higher rate of PSE.

329 Regarding the NIHSS score, higher score cause higher incidence rate

of PSE .Higher values of WBC count, D-dimer, CRP, AST, CK-MB, HbA1c, bilirubin, 330 331 TCO2, and LDH at admission were associated with a greater likelihood of developing PSE. Conversely, lower values of HBDH, PLT, and APTT were also linked to a higher 332 probability of the outcome. However, the specific regions of the brain affected did not 333 have a significant individual effect on the overall outcome. Among the complications, 334 only hypertension was more strongly associated with the development of the outcome. 335 Other conditions, such as coronary heart disease, diabetes, hyperlipidemia, and fatty liver, 336 were less likely to be related to the outcome. We use the force plot of the first person to 337 338 show the influence of different features of the first person, we can see that long APTT 339 time contribute best to PSE, then the AST level and others, the NIHSS score may be low 340 and contribute opposite to the final result. Then the decision plot is a collection of model decisions that show how complex models arrive at their predictions. 341

342 **Discussion**

Our study utilized comprehensive clinical data, imaging data, laboratory test data, from the database of the stroke patients and employed machine learning algorithms to establish a predictive model, achieving an AUC score of above 0.95, which demonstrated more accurate predictions compared to traditional statistical methods. Our research found that tree-based ensemble models showed superior overall prediction capabilities when dealing with large sample sizes and high-dimensional features.

During the modeling process, due to the extreme imbalance between negative and
positive samples, we employed SMOTEENN technique to resample an imbalanced
dataset for machine learning, resulting in improved training performance. Through SHAP
analysis, we conducted interpretability analysis of the model and determined the
importance of different features.

354 In our study, age and NIHSS score were treated as continuous variables. We found that, overall, female patients, older patients, and those with higher NIHSS scores were 355 356 more prone to develop PSE, which is consistent with recent articles. High NIHSS scores, indicative of more severe stroke, increased the risk of complications, ranking only to 357 white blood cell count and d-dimer in our model [5][19][10][20]. However, there are 358 359 conflicting opinions regarding the impact of age. Some researchs [5][21] suggested that age <65 is a high-risk factor, which aligns with our findings, while some studies [22] 360 confirmed that advanced age is the determining factor. Yamada et al. [21] also concurred 361 362 with our study in identifying a higher risk of complications among females, whereas Waafi et al. [10] indicated that the likelihood of male patients developing complications 363 364 is 3.325 times that of females, which contradicts our findings.

Previous studies have shown that patients with diabetes, dyslipidemia, hypertension, 365 depression, or dementia are at an increased risk of developing vascular epilepsy [12]. In 366 our study, statistics and multiple ML models analyzed the association between 367 368 comorbidities and complications, revealing that patients with coronary heart disease, diabetes, fatty liver, hyperlipidemia, or large artery stenosis or plaques(CCA and ICA) 369 were less likely to develop epilepsy. According to the TOAST classification, ischemic 370 stroke is categorized into five types: large artery atherosclerosis, cardioembolism, small 371 vessel occlusion, other determined etiology, and undetermined etiology. Patients with 372 combined comorbidities generally fall into the categories of large artery atherosclerosis 373 374 and cardioembolism, which are relatively well-defined and easier to intervene, thus 375 resulting in a lower likelihood of developing epilepsy. Conversely, strokes with undetermined etiology usually have a poor prognosis and are more likely to lead to 376 epilepsy. Among diabetes patients, higher HbA1c levels indicate poorer blood sugar 377 control, resulting in a higher probability of developing complications, which significantly 378 affects certain patients, while those with good control have a lower overall risk of 379 developing complications. 380

Alain et al. found that cortical infarction was more likely to result in epilepsy in 381 382 patients hospitalized with anterior circulation ischemic stroke [23]. Lin et al. found that 383 factors such as cortical involvement and intracerebral hemorrhage volume increased the 384 likelihood of PSE, which is consistent with our research findings [8]. Al-Sahli et al. also suggested that cortical brain injury and large-area lesions increased the risk of PSE 385 386 [5][21]. In our study, statistics showed affections of cortical and subcortical regions both increased the possibility of PSE, but had lower affection than the other features so didn't 387 be selected in lasso regression. 388

Previous studies have found that acute infection is a risk factor for ischemic stroke 389 [24]. C-reactive protein (CRP) reflects the level of inflammation and is an independent 390 391 prognostic factor [25]. In our study, regression and SHAP analysis both showed that white blood cell count had great impact among the routine blood test parameters, in 392 SHAP it even surpassed the NIHSS score. High white blood cell count may indicate 393 severe inflammation and infection, as well as increased blood viscosity, making patients 394 395 more susceptible to secondary complications. In general, high red blood cell count and 396 low platelet count also have some influence.

397 A large-scale study on Chinese individuals found a negative correlation between 398 plasma high-density lipoprotein cholesterol (HDL-C) concentration and the risk of ischemic stroke, a weak positive correlation between plasma triglyceride (TG) 399 400 concentration and the risk of ischemic stroke, and a strong correlation between plasma low-density lipoprotein cholesterol (LDL-C) concentration and apolipoprotein B [26]. 401 High HDL-C levels are associated with better prognosis [27]. Our study is consistent with 402 previous research, indicating that high LDL-C, low HDL-C, and high TG levels are more 403 404 likely to lead to PSE. This can be easily understood as high cholesterol and triglyceride levels lead to increased blood viscosity and vascular sclerosis, making it easier for clots 405 to form [12][28][29]. Higher D-dimer levels indicate greater brain tissue damage and a 406 407 higher likelihood of PSE. Overall, lower activated partial thromboplastin time (APTT) and fibrinogen levels are associated with an increased risk of PSE. INR, PT, and TT have 408 a smaller impact. Among liver function parameters, aspartate aminotransferase (AST) has 409 the greatest influence on PSE, while high AST levels, low alanine aminotransferase (ALT) 410 levels, and low albumin levels all have a certain degree of impact. Lingling Ding et al. 411 found that liver enzyme subgroups characterized by alanine aminotransferase and 412 413 aspartate aminotransferase were associated with a high risk of adverse function [30], 414 which is consistent with our research.

415 Studies have shown that subgroups identified by renal function biomarkers such as 416 urinary microalbumin, cystatin C, and creatinine have significantly higher stroke recurrence and poorer prognosis [30]. In our study, low urea levels and high uric acid 417 418 levels had a negative impact [31][32][33]. Our research is similar to their conclusions. While elevated uric acid levels at admission are positively associated with PSE, patients 419 420 previously diagnosed with hyperuricemia are less likely to develop epilepsy. Considering 421 that uric acid functions as a strong reducing agent and has neuroprotective properties [34], 422 patients with normal liver and kidney function and a certain degree of hyperuricemia have stronger resistance to emergencies [35][36]. However, excessively high uric acid 423 424 levels indicate metabolic disorders and poor liver and kidney function, which are associated with poor prognosis. 425

When stroke patients are admitted, cardiac enzyme profile tests are often performed 426 to rule out concurrent myocardial ischemia. However, studies have shown that elevated 427 428 CK-MB in stroke patients may not only be related to the heart [37]. Multiple cardiac enzymes are important prognostic indicators [38][39] and have been included in stroke 429 scores [40]. Some studies have shown a higher incidence of abnormal serum cardiac 430 enzyme profiles in the acute phase of stroke. Although the incidence of abnormalities is 431 unrelated to the nature of the stroke, it is associated with the severity of the stroke, with 432 patients with consciousness disorders having a significantly higher incidence of abnormal 433 434 cardiac enzyme profiles than those without consciousness disorders [41]. In our study, CK, CK-MB, and IMA in the cardiac enzyme profile had a significant impact and high 435 436 predictive value, but the specific mechanisms require further research [34].

Although our study incorporates a large amount of information and utilizes almost
all available data, including clinical data, imaging data, and laboratory test data, in an
attempt to establish more accurate prediction models beyond traditional statistics using
machine learning algorithms, there are still several limitations in the modeling process.

While the current study provides valuable insights, the data sample may not be fully
representative, and the model's generalization ability requires further assessment.
Although the data was collected from multiple tertiary hospitals, encompassing over
20,000 cases, earlier data was lost due to hospital system upgrades. The collected data
mainly represents patients diagnosed in the past five years and is primarily concentrated
in the Chongqing region, which may limit the model's applicability to other geographic
areas.

Additionally, the retrospective nature of the research has resulted in the lack of
certain important predictive indicators. As this was a retrospective study, many
potentially meaningful features, such as hemorheology, thromboelastography, and
hormone levels, were significantly missing and had to be excluded. Incorporating these
additional features could potentially improve the model's accuracy.

To enhance the predictive power of the model, it would be beneficial to incorporate more beyond baseline patient characteristics. For example, the current analysis primarily utilized the results of the first examination upon admission, without fully leveraging the information from subsequent examinations. In future research, the use of recurrent neural networks could facilitate the comprehensive extraction of features from the entire sequence of examinations.

To further strengthen the study, data standardization should be improved, and the number of cases and important indicators should continue to increase. Additionally, it would be advisable to explore more advanced scientific methods, such as deep learning, and fully leverage all available data to make more accurate predictions.

463 **Conclusion**

We developed an interpretable machine learning model to predict the risk of post-464 stroke epilepsy (PSE) in hospitalized patients with ischemic stroke. Leveraging a large 465 volume of medical records, our artificial intelligence model demonstrates good predictive 466 performance for PSE. The key predictors identified by the model include NIHSS score, D-467 dimer levels, lactate levels, and white blood cell count, followed by indicators related to 468 469 liver function and cardiac enzyme profiles. The transparency and interpretability of the model's predictions can foster trust among clinical practitioners and facilitate decision-470 making. While the results are promising, further prospective studies are needed to validate 471 472 the clinical utility of this tool before its application in real-world settings.

- 473
- 474
- 475
- 476 477
- 478
- 479
- 480
- 481
- 482
- 483

Feigin V L, Krishnamurthi R V, Theadom A M, et al.. Global, Regional, and
National Burden of Neurological Disorders during 1990–2015: A Systematic
Analysis for the Global Burden of Disease Study 2015[J]. The Lancet Neurology,
2017, 16(11): 877–897.

488 [2] Galovic M, Döhler N, Erdélyi-Canavese B, et al.. Prediction of Late Seizures
489 after Ischaemic Stroke with a Novel Prognostic Model (the SeLECT Score): A
490 Multivariable Prediction Model Development and Validation Study[J]. The Lancet
491 Neurology, 2018, 17(2): 143.

492 [3] Krishnamurthi R V, Feigin V L, Forouzanfar M H, et al.. Global and Regional
493 Burden of First-Ever Ischaemic and Haemorrhagic Stroke during 1990–2010:
494 Findings from the Global Burden of Disease Study 2010[J]. The Lancet Global Health,
495 2013, 1(5): e259–e281.

496 [4] Zhao Y, Li X, Zhang K, et al.. The Progress of Epilepsy after Stroke[J]. Curr
497 Neuropharmacol, 2018, 16(1): 71–78.

498 [5] Al-Sahli O a M, Tibekina L, Subbotina O P, et al.. Post-Stroke Epileptic Seizures:
499 Risk Factors, Clinical Presentation, Principles of Diagnosis and Treatment[J].
500 Epilepsy and paroxysmal conditions, 2023, 15(2): 148–159.

501 [6] Chen Z, Churilov L, Chen Z, et al.. Association between Implementation of a 502 Code Stroke System and Poststroke Epilepsy[J]. Neurology, 2018, 90(13): e1126– 503 e1133.

504 [7] Merkler A E, Gialdini G, Lerario M P, et al.. Population-Based Assessment of
505 the Long-Term Risk of Seizures in Survivors of Stroke[J]. Stroke, 2018, 49(6): 1319–
506 1324.

507 [8] Lin R, Lin J, Xu Y, et al.. Development and Validation of a Novel Radiomics508 Clinical Model for Predicting PSE after First-Ever Intracerebral Haemorrhage[J].
509 European Radiology, 2023, 33(7): 4526–4536.

- 510 [9] Pszczolkowski S, Law Z K. Editorial Comment on 《Development and
 511 Validation of a Novel Radiomics-Clinical Model for Predicting PSE after First-Ever
 512 Intracerebral Haemorrhage》 [J]. European Radiology, 2023, 33(7): 4524–4525.
- [10] Waafi A K, Husna M, Damayanti R, et al.. Clinical Risk Factors Related to PSE
 Patients in Indonesia: A Hospital-Based Study[J]. Egyptian Journal of Neurology,
 Psychiatry and Neurosurgery, 2023, 59(1).
- [11] Herzig-Nichtweiß J, Salih F, Berning S, et al.. Prognosis and Management of
 Acute Symptomatic Seizures: A Prospective, Multicenter, Observational Study[J].
 Annals of Intensive Care, 2023, 13(1).
- 519 [12] Pitkänen A, Roivainen R, Lukasiuk K. Development of Epilepsy after 520 Ischaemic Stroke[]]. The Lancet Neurology, 2016, 15(2): 185–197.

The Artificial Intelligence Revolution in Stroke Care: A Decade of Scientific 521 [13] Evidence in Review[J]. World Neurosurgery, Elsevier, 2024. 522 Predicting Stroke and Myocardial Infarction Risk in Takayasu Arteritis with [14] 523 524 Automated Machine Learning Models[]]. iScience, Elsevier, 2023, 26(12): 108421. Daidone M. Ferrantelli S. Tuttolomondo A. et al., Machine Learning [15] 525 526 Applications in Stroke Medicine: Advancements, Challenges, and Future 527 Prospective[I]. Neural Regeneration Research, 2024, 19(4): 769–773. Lee M, Yeo N-Y, Ahn H-J, et al.. Prediction of Post-Stroke Cognitive 528 [16] Impairment after Acute Ischemic Stroke Using Machine Learning[]]. Alzheimer's 529 530 Research and Therapy, 2023, 15(1). [17] Gong J, Zhang Y, Zhong X, et al.. Liver Function Test Indices-Based Prediction 531 532 Model for Post-Stroke Depression: A Multicenter, Retrospective Study[]]. BMC Medical Informatics and Decision Making, 2023, 23(1). 533 534 [18] He H, Liu J, Li C, et al.. Predicting Hematoma Expansion and Prognosis in 535 Cerebral Contusions: A Radiomics-Clinical Approach[]]. Journal of Neurotrauma, 2024: neu.2023.0410. 536 Lin R, Yu Y, Wang Y, et al., Risk of PSE Following Stroke-Associated Acute 537 [19] 538 Symptomatic Seizures[J]. Frontiers in Aging Neuroscience, 2021, 13. Zöllner I P. Misselwitz B. Kaps M. et al., National Institutes of Health Stroke 539 [20] Scale (NIHSS) on Admission Predicts Acute Symptomatic Seizure Risk in Ischemic 540 Stroke: A Population-Based Study Involving 135,117 Cases[]]. Scientific Reports, 541 2020, 10(1). 542 Yamada S, Nakagawa I, Tamura K, et al., Investigation of Poststroke Epilepsy 543 [21] (INPOSE) Study: A Multicenter Prospective Study for Prediction of Poststroke 544 Epilepsy[J]. J Neurol, 2020, 267(11): 3274–3281. 545 546 [22] Lidetu T, Zewdu D. Incidence and Predictors of Post Stroke Seizure among Adult Stroke Patients Admitted at Felege Hiwot Compressive Specialized Hospital. 547 548 Bahir Dar, North West Ethiopia, 2021: A Retrospective Follow up Study[]]. BMC Neurology, 2023, 23(1). 549 550 [23] Lekoubou A, Ssentongo P, Maffie J, et al.. Associations of Small Vessel Disease and Acute Symptomatic Seizures in Ischemic Stroke Patients[]]. Epilepsy & Behavior, 551 552 2023, 145: 109233. 553 Bova I Y, Bornstein N M, Korczyn. Acute Infection as a Risk Factor for [24] 554 Ischemic Stroke[J]. Stroke, 1996, 27(12): 2204–2206. Di Napoli M. Papa F. Bocola V. C-Reactive Protein in Ischemic Stroke an [25] 555 Independent Prognostic Factor[]]. Stroke, 2001, 32(4): 917–924. 556

557 [26] Sun L, Clarke R, Bennett D, et al.. Causal Associations of Blood Lipids with

- Risk of Ischemic Stroke and Intracerebral Hemorrhage in Chinese Adults[J]. Nat Med,
 Nature Publishing Group, 2019, 25(4): 569–574.
- 560 [27] Bandeali S, Farmer J. High-Density Lipoprotein and Atherosclerosis: The Role 561 of Antioxidant Activity[J]. Current Atherosclerosis Reports, 2012, 14(2): 101–107.
- 562 [28] Gasparini S, Neri S, Brigo F, et al.. Late Epileptic Seizures Following Cerebral
 563 Venous Thrombosis: A Systematic Review and Meta-Analysis[J]. Neurol Sci, 2022,
 564 43(9): 5229–5236.
- 565 [29] Abraira L, Giannini N, Santamarina E, et al.. Correlation of Blood Biomarkers
 566 with Early-Onset Seizures after an Acute Stroke Event[J]. Epilepsy & Behavior, 2020,
 567 104: 106549.
- [30] Ding L, Liu Y, Meng X, et al.. Biomarker and Genomic Analyses Reveal
 Molecular Signatures of Non-Cardioembolic Ischemic Stroke[J]. Sig Transduct Target
 Ther, Nature Publishing Group, 2023, 8(1): 1–16.
- [31] Zhang W, Cheng Z, Fu F, et al.. Serum Uric Acid and Prognosis in Acute
 Ischemic Stroke: A Dose-Response Meta-Analysis of Cohort Studies[J]. Frontiers in
- 573 Aging Neuroscience, 2023, 15.
- 574 [32] Wang D, Hu B, Dai Y, et al.. Serum Uric Acid Is Highly Associated with 575 Epilepsy Secondary to Cerebral Infarction[J]. Neurotox Res, 2019, 35(1): 63–70.
- 576 [33] Wang C, Cui T, Wang L, et al.. Prognostic Significance of Uric Acid Change in
 577 Acute Ischemic Stroke Patients with Reperfusion Therapy[J]. Eur J Neurol, 2021,
 578 28(4): 1218–1224.
- 579 [34] Ng G J L, Quek A M L, Cheung C, et al.. Stroke Biomarkers in Clinical Practice:
 580 A Critical Appraisal[J]. NeuROChemistry International, 2017, 107: 11–22.
- [35] Amaro S, Urra X, Gómez-Choco M, et al.. Uric Acid Levels Are Relevant in
 Patients With Stroke Treated With Thrombolysis[J]. Stroke, American Heart
 Association, 2011, 42(1_suppl_1): S28–S32.
- [36] Amaro S, Urra X, Gómez-Choco M, et al.. Uric Acid Levels Are Relevant in
 Patients with Stroke Treated with Thrombolysis[J]. Stroke, 2011, 42(SUPPL. 1):
 S28–S32.
- [37] Ay H, Arsava E M, Sarba O. Creatine Kinase-MB Elevation after Stroke Is Not
 Cardiac in Origin Comparison with Troponin T Levels[J]. Stroke, 2002, 33(1): 286–
 289.
- 590 [38] Liu X, Chen X, Wang H, et al.. Prognostic Significance of Admission Levels of
 591 Cardiac Indicators in Patients with Acute Ischaemic Stroke: Prospective
 592 Observational Study[]]. J Int Med Res, SAGE Publications Ltd, 2014, 42(6): 1301–
- 593 1310.

594 [39] Zeng Y-Y, Zhang W-B, Cheng L, et al.. Cardiac Parameters Affect Prognosis in

595 Patients with Non-Large Atherosclerotic Infarction[J]. Molecular Medicine, 2021,596 27(1): 2.

597 [40] Hijazi Z, Lindbäck J, Alexander J H, et al.. The ABC (Age, Biomarkers, Clinical
 598 History) Stroke Risk Score: A Biomarker-Based Risk Score for Predicting Stroke in

- History) Stroke Risk Score: A Biomarker-Based Risk Score for Predicting St
 Atrial Fibrillation[]]. European Heart Journal, 2016, 37(20): 1582–1590.
- 600 [41] Zheng Yuan-Hui, ZHENG Jin-Yi, ZHANG Jian. Changes of serum myocardial
- 601 enzyme profile in acute stage of stroke [J]. Chinese Journal of Advanced Medical
- 602 Doctors, China Medical Journal, 2009, 32(07): 46 -- 47.



Figure 1.Selection and exclusion procedure of patients



Figure 2 LASSO Regression Coefficient Paths



Figure 3. ROC of train(A1), ROC of test(B1), CC of train(A2), CC of test(B2), PCA of train(A3), PCA of test(B3)



Figure 4.SHAP value(left), force plot(upper right) and decision plot (lower right)

stats	Р	method	negative, N = 20789	positive, N=954	Feature
0.59897	0.438971	Chi-Square	-	-	eca_plaque
-	-	-	20591 (99.048%)	942 (98.742%)	0
-	-	-	198 (0.952%)	12 (1.258%)	1
10.381551	0.001273	Chi-Square	-	-	subcortex_lobe
-	-	-	18454 (88.768%)	814 (85.325%)	0
-	-	-	2335 (11.232%)	140 (14.675%)	1
0.000127	0.991017	Chi-Square	-	-	ba
-	-	-	20605 (99.115%)	945 (99.057%)	0
-	-	-	184 (0.885%)	9 (0.943%)	1
0.271184	0.602539	Chi-Square	-	-	hypertension

-	-	-	6497 (31.252%)	290 (30.398%)	——0
-	-	-	14292 (68.748%)	664 (69.602%)	——1
2.051203	0.152086	Chi-Square	-	-	ica_plaque
-	-	-	19392 (93.28%)	878 (92.034%)	——0
-	-	-	1397 (6.72%)	76 (7.966%)	——1
53.171781	0	Chi-Square	-	-	frontal_lobe
-	-	-	19943 (95.931%)	868 (90.985%)	——0
-	-	-	846 (4.069%)	86 (9.015%)	1
17.284355	0.000032	Chi-Square	-	-	cerebral_hernia
-	-	-	20626 (99.216%)	934 (97.904%)	——0
-	-	-	163 (0.784%)	20 (2.096%)	——1
3.512207	0.060918	Chi-Square	-	-	thalamus
-	-	-	20565 (98.923%)	937 (98.218%)	——0
-	-	-	224 (1.077%)	17 (1.782%)	1
17.17679	0.000034	Chi-Square	-	-	occipital_lobe
-	-	-	20422 (98.235%)	919 (96.331%)	——0
-	-	-	367 (1.765%)	35 (3.669%)	——1
0.018717	0.891182	Chi-Square	-	-	рса
-	-	-	20729 (99.711%)	952 (99.79%)	——0
-	-	-	60 (0.289%)	2 (0.21%)	——1
1.545786	0.213759	Chi-Square	-	-	paraventricular
-	-	-	19786 (95.175%)	899 (94.235%)	——0
-	-	-	1003 (4.825%)	55 (5.765%)	1
0.729435	0.393066	Chi-Square	-	-	mca
-	-	-	19998 (96.195%)	912 (95.597%)	——0
-	-	-	791 (3.805%)	42 (4.403%)	——1
26.19087	0	Chi-Square	-	-	coronary_disease

-	-	-	11288 (54.298%)	599 (62.788%)	——0
-	-	-	9501 (45.702%)	355 (37.212%)	——1
53.351931	0	Chi-Square	-	-	hypoproteinemia
-	-	-	18479 (88.888%)	774 (81.132%)	——0
-	-	-	2310 (11.112%)	180 (18.868%)	——1
57.137771	0	Chi-Square	-	-	parietal_lobe
-	-	-	20180 (97.071%)	884 (92.662%)	——0
-	-	-	609 (2.929%)	70 (7.338%)	——1
0.007944	0.928981	Chi-Square	-	-	аса
-	-	-	20524 (98.725%)	941 (98.637%)	——0
-	-	-	265 (1.275%)	13 (1.363%)	——1
1.096759	0.294979	Chi-Square	-	-	brainstem
-	-	-	20532 (98.764%)	938 (98.323%)	——0
-	-	-	257 (1.236%)	16 (1.677%)	——1
25.147468	0.000001	Chi-Square	-	-	hyperuricemia
-	-	-	18547 (89.215%)	801 (83.962%)	——0
-	-	-	2242 (10.785%)	153 (16.038%)	——1
57.872112	0	Chi-Square	-	-	temporal_lobe
-	-	-	20209 (97.21%)	886 (92.872%)	——0
-	-	-	580 (2.79%)	68 (7.128%)	——1
0.739172	0.389926	Chi-Square	-	-	diabetes
-	-	-	13737 (66.078%)	617 (64.675%)	——0
-	-	-	7052 (33.922%)	337 (35.325%)	——1
85.377485	0	Chi-Square	-	-	range_lobe
-	-	-	19559 (94.083%)	830 (87.002%)	——0
-	-	-	467 (2.246%)	43 (4.507%)	1
-	_	-	329 (1.583%)	32 (3.354%)	——2

——3	31 (3.249%)	224 (1.077%)	-	-	-
——4	15 (1.572%)	175 (0.842%)	-	-	-
——5	3 (0.314%)	35 (0.168%)	-	-	-
epencephalon	-	-	Chi-Square	1	0
——0	934 (97.904%)	20362 (97.946%)	-	-	-
1	20 (2.096%)	427 (2.054%)	-	-	-
hydrocephalus	-	-	Chi-Square	0	181.23517
——0	895 (93.816%)	20565 (98.923%)	-	-	-
1	59 (6.184%)	224 (1.077%)	-	-	-
insular_lobe	-	-	Chi-Square	0.391042	0.735699
——0	938 (98.323%)	20519 (98.701%)	-	-	-
——1	16 (1.677%)	270 (1.299%)	-	-	-
gender	-	-	Chi-Square	0	44.244052
——0	372 (38.994%)	10407 (50.06%)	-	-	-
——1	582 (61.006%)	10382 (49.94%)	-	-	-
uremia	-	-	Chi-Square	0.00008	15.568169
——0	934 (97.904%)	20618 (99.177%)	-	-	-
1	20 (2.096%)	171 (0.823%)	-	-	-
atrial_fibrillation	-	-	Chi-Square	0.008017	7.029734
——0	838 (87.841%)	18811 (90.485%)	-	-	-
1	116 (12.159%)	1978 (9.515%)	-	-	-
centrum_semiovale	-	-	Chi-Square	0.36206	0.830735
——0	922 (96.646%)	20207 (97.2%)	-	-	-
1	32 (3.354%)	582 (2.8%)	-	-	-
basal_ganglia	-	-	Chi-Square	0.005355	7.755329
——0	893 (93.606%)	19869 (95.575%)	-	-	-
——1	61 (6.394%)	920 (4.425%)	-	-	-

d∨t	-	-	Chi-Square	0	40.790867
——0	847 (88.784%)	19534 (93.963%)	-	-	-
——1	107 (11.216%)	1255 (6.037%)	-	-	-
fatty_liver	-	-	Chi-Square	0.000171	14.123893
——0	812 (85.115%)	16655 (80.114%)	-	-	-
——1	142 (14.885%)	4134 (19.886%)	-	-	-
hyperlipidaemia	-	-	Chi-Square	0.000317	12.969155
——0	801 (83.962%)	16439 (79.075%)	-	-	-
——1	153 (16.038%)	4350 (20.925%)	-	-	-
cca_plaque	-	-	Chi-Square	0.376965	0.780577
——0	751 (78.721%)	16100 (77.445%)	-	-	-
——1	203 (21.279%)	4689 (22.555%)	-	-	-
va	-	-	Chi-Square	0.797483	0.065847
——0	927 (97.17%)	20159 (96.97%)	-	-	-
——1	27 (2.83%)	630 (3.03%)	-	-	-
fibrinogen	3.518 ± 0.663	3.602 ± 0.464	Mann- Whitney U	0.434584	10064078.5
d_dimer	4.362 ± 4.398	1.198 ± 0.98	Mann- Whitney U	0	3555180.5
bua	342.521 ± 74.651	344.132 ± 58.336	Mann- Whitney U	0.000037	10698805.5
tco2	22.739 ± 1.025	22.781 ± 1.225	Mann- Whitney U	0.166751	10178363
hbdh	209.295 ± 57.826	175.906 ± 48.18	Mann- Whitney U	0	6107843
anion_gap	13.026 ± 1.456	12.345 ± 1.368	Mann- Whitney U	0	6496800
ldl	2.686 ± 0.372	2.685 ± 0.361	Mann- Whitney U	0.23394	10140916.5

7950954.5	0	Mann- Whitney U	16.432 ± 0.615	16.636 ± 0.809	tt
2984725.5	0	Mann- Whitney U	7.886 ± 2.871	11.529 ± 2.564	nihss
10338834.5	0.025821	Mann- Whitney U	40.886 ± 2.257	40.734 ± 2.37	albumin
9016933.5	0	Mann- Whitney U	1.076 ± 0.149	1.068 ± 0.072	inr
7582690.5	0	Mann- Whitney U	1.536 ± 0.433	1.662 ± 0.484	tg
7522775	0	Mann- Whitney U	15.197 ± 3.981	16.516 ± 4.009	bilirubin
4487861	0	Mann- Whitney U	75.458 ± 12.891	81.624 ± 8.559	ima
8374380.5	0	Mann- Whitney U	13.843 ± 1.151	13.822 ± 0.627	pt
3060302	0	Mann- Whitney U	15.314 ± 18.865	55.681 ± 48.823	crp
2667973	0	Mann- Whitney U	8.316 ± 1.286	11.79 ± 3.084	wbc
10386092	0.013188	Mann- Whitney U	66.806 ± 12.597	65.335 ± 13.909	age
10008026	0.619502	Mann- Whitney U	1.249 ± 0.149	1.246 ± 0.146	hdl
4480425	0	Mann- Whitney U	2.505 ± 0.411	2.825 ± 0.376	lactate
7811417	0	Mann- Whitney U	4.304 ± 0.324	4.408 ± 0.274	rbc
3814876	0	Mann- Whitney U	26.05 ± 12.823	38.25 ± 18.205	ast
11826502.5	0	Mann- Whitney U	190.132 ± 26.424	180.251 ± 36.939	plt
7632233.5	0	Mann- Whitney U	24.193 ± 10.108	26.827 ± 10.349	alt

aptt	35.045 ± 1.881	35.702 ± 2.313	Mann- Whitney U	0	11737054.5
ldh	296.455 ± 111.282	215.357 ± 75.036	Mann- Whitney U	0	5261997.5
creatinine	83.837 ± 24.574	85.199 ± 52.439	Mann- Whitney U	0	8567930.5
hba1c	6.759 ± 1.048	6.662 ± 0.916	Mann- Whitney U	0.000035	9132523
urea	6.33 ± 1.354	6.419 ± 1.438	Mann- Whitney U	0.001566	10515532
ck	1029.594 ± 872.8	195.007 ± 273.212	Mann- Whitney U	0	3469376

Table 1.Single factor significant analysis results

Feature	0 (N=207 89)	1 (N=954)	OR (univariabl e)	coe f	std err	Z	P > z	[0. 02 5	0.9 75]	Label_1	Label_0
age	66.806 ± 12.597	65.335 ± 13.909	0.991 (0.986- 0.996, p=0.0)	- 0.0 090	0.0 03	- 3.5 08	0. 00 0	- 0.0 14	- 0.0 04	-	-
plt	190.13 2 ± 26.424	180.25 1 ± 36.939	0.986 (0.983- 0.988, p=0.0)	- 0.0 141	0.0 01	- 11. 32 0	0. 00 0	- 0.0 17	- 0.0 12	-	-
wbc	8.316 ± 1.286	11.79 ± 3.084	2.23 (2.149- 2.314, p=0.0)	0.8 022	0.0 19	42. 30 6	0. 00 0	0.7 65	0.8 39	-	-
rbc	4.304 ± 0.324	4.408 ± 0.274	2.622 (2.162- 3.177, p=0.0)	0.9 638	0.0 98	9.8 05	0. 00 0	0.7 71	1.1 56	-	-
hba1c	6.662 ± 0.916	6.759 ± 1.048	1.112 (1.042- 1.186, p=0.001)	0.1 059	0.0 33	3.1 76	0. 00 1	0.0 41	0.1 71	-	-
crp	15.314 ± 18.865	55.681 ± 48.823	1.033 (1.031- 1.035,	0.0 326	0.0 01	36. 79	0. 00	0.0 31	0.0 34	-	-

			p=0.0)			2	0				
tg	1.536 ± 0.433	1.662 ± 0.484	1.617 (1.441- 1.815, p=0.0)	0.4 807	0.0 59	8.1 70	0. 00 0	0.3 65	0.5 96	-	-
ldl	2.685 ± 0.361	2.686 ± 0.372	1.009 (0.843- 1.207, p=0.924)	0.0 087	0.0 91	0.0 95	0. 92 4	- 0.1 71	0.1 88	-	-
hdl	1.249 ± 0.149	1.246 ± 0.146	0.87 (0.562- 1.349, p=0.534)	- 0.1 389	0.2 23	- 0.6 22	0. 53 4	- 0.5 77	0.2 99	-	-
ast	26.05 ± 12.823	38.25 ± 18.205	1.028 (1.024- 1.031, p=0.0)	0.0 277	0.0 02	17. 00 7	0. 00 0	0.0 24	0.0 31	-	-
alt	24.193 ± 10.108	26.827 ± 10.349	1.017 (1.012- 1.021, p=0.0)	0.0 169	0.0 02	7.5 07	0. 00 0	0.0 12	0.0 21	-	-
bilirubin	15.197 ± 3.981	16.516 ± 4.009	1.068 (1.054- 1.082, p=0.0)	0.0 662	0.0 07	9.8 26	0. 00 0	0.0 53	0.0 79	-	-
albumin	40.886 ± 2.257	40.734 ± 2.37	0.971 (0.945- 0.999, p=0.042)	- 0.0 291	0.0 14	- 2.0 36	0. 04 2	- 0.0 57	- 0.0 01	-	-
urea	6.419 ± 1.438	6.33 ± 1.354	0.955 (0.91- 1.002, p=0.063)	- 0.0 459	0.0 25	- 1.8 62	0. 06 3	- 0.0 94	0.0 02	-	-
creatinin e	85.199 ± 52.439	83.837 ± 24.574	0.999 (0.998- 1.001, p=0.425)	- 0.0 006	0.0 01	- 0.7 98	0. 42 5	- 0.0 02	0.0 01	-	-
bua	344.13 2 ± 58.336	342.52 1 ± 74.651	1.0 (0.998- 1.001, p=0.411)	- 0.0 005	0.0 01	- 0.8 22	0. 41 1	- 0.0 02	0.0 01	-	-
pt	13.843 ± 1.151	13.822 ± 0.627	0.982 (0.925- 1.043, p=0.564)	- 0.0 177	0.0 31	- 0.5 77	0. 56 4	- 0.0 78	0.0 42	-	-

aptt	35.702 ± 2.313	35.045 ± 1.881	0.863 (0.835- 0.891, p=0.0)	- 0.1 473	0.0 17	- 8.9 17	0. 00 0	- 0.1 80	- 0.1 15	-	-
tt	16.432 ± 0.615	16.636 ± 0.809	1.411 (1.287- 1.547, p=0.0)	0.3 442	0.0 47	7.3 28	0. 00 0	0.2 52	0.4 36	-	-
inr	1.076 ± 0.149	1.068 ± 0.072	0.643 (0.385- 1.074, p=0.091)	- 0.4 421	0.2 62	- 1.6 89	0. 09 1	- 0.9 55	0.0 71	-	-
d_dimer	1.198 ± 0.98	4.362 ± 4.398	1.717 (1.662- 1.774, p=0.0)	0.5 405	0.0 17	32. 72 4	0. 00 0	0.5 08	0.5 73	-	-
fibrinoge n	3.602 ± 0.464	3.518 ± 0.663	0.675 (0.585- 0.778, p=0.0)	- 0.3 931	0.0 73	- 5.4 08	0. 00 0	- 0.5 36	- 0.2 51	-	-
ck	195.00 7 ± 273.21 2	1029.5 94 ± 872.8	1.002 (1.002- 1.002, p=0.0)	0.0 024	6.1 5e- 05	38. 32 6	0. 00 0	0.0 02	0.0 02	-	-
ldh	215.35 7 ± 75.036	296.45 5 ± 111.28 2	1.005 (1.005- 1.006, p=0.0)	0.0 053	0.0 00	21. 42 4	0. 00 0	0.0 05	0.0 06	-	-
hbdh	175.90 6 ± 48.18	209.29 5 ± 57.826	1.006 (1.005- 1.007, p=0.0)	0.0 062	0.0 00	15. 63 7	0. 00 0	0.0 05	0.0 07	-	_
ima	75.458 ± 12.891	81.624 ± 8.559	1.015 (1.012- 1.017, p=0.0)	0.0 147	0.0 01	10. 70 7	0. 00 0	0.0 12	0.0 17	-	-
lactate	2.505 ± 0.411	2.825 ± 0.376	3.12 (2.784- 3.494, p=0.0)	1.1 377	0.0 58	19. 58 7	0. 00 0	1.0 24	1.2 51	_	_
anion_ga	12.345 ± 1.368	13.026 ± 1.456	1.344 (1.29- 1.399, p=0.0)	0.2 953	0.0 21	14. 36 8	0. 00 0	0.2 55	0.3 36	_	_
tco2	22.781	22.739	0.972 (0.921-	- 0.0	0.0	- 1.0	0.	- 0.0	0.0	-	-

	± 1.225	± 1.025	1.025, p=0.293)	287	27	51	29 3	82	25		
nihss	7.886 ± 2.871	11.529 ± 2.564	1.342 (1.318- 1.368, p=0.0)	0.2 942	0.0 10	30. 95 7	0. 00 0	0.2 76	0.3 13	-	-
uremia_ 0	20618 (99.177 %)	934 (97.904 %)	-	-	-	-	-	-	-	4.334% (934 / 21552)	95.666% (20618 / 21552)
uremia_ 1	171 (0.823 %)	20 (2.096 %)	2.582 (1.618- 4.121, p=0.0)	0.9 485	0.2 39	3.9 74	0. 00 0	0.4 81	1.4 16	10.471% (20 / 191)	89.529% (171 / 191)
dvt_0	19534 (93.963 %)	847 (88.784 %)	-	-	-	-	-	-	-	4.156% (847 / 20381)	95.844% (19534 / 20381)
dvt_1	1255 (6.037 %)	107 (11.216 %)	1.966 (1.595- 2.423, p=0.0)	0.6 761	0.1 07	6.3 40	0. 00 0	0.4 67	0.8 85	7.856% (107 / 1362)	92.144% (1255 / 1362)
fatty_live r_0	16655 (80.114 %)	812 (85.115 %)	-	-	-	-	-	-	-	4.649% (812 / 17467)	95.351% (16655 / 17467)
fatty_live r_1	4134 (19.886 %)	142 (14.885 %)	0.705 (0.587- 0.845, p=0.0)	- 0.3 502	0.0 93	- 3.7 82	0. 00 0	- 0.5 32	- 0.1 69	3.321% (142 / 4276)	96.679% (4134 / 4276)
diabetes _0	13737 (66.078 %)	617 (64.675 %)	-	-	-	-	-	-	-	4.298% (617 / 14354)	95.702% (13737 / 14354)
diabetes _1	7052 (33.922 %)	337 (35.325 %)	1.064 (0.929- 1.219, p=0.371)	0.0 620	0.0 69	0.8 95	0. 37 1	- 0.0 74	0.1 98	4.561% (337 / 7389)	95.439% (7052 / 7389)
hyperten sion_0	6497 (31.252 %)	290 (30.398 %)	-	-	-	-	-	-	-	4.273% (290 / 6787)	95.727% (6497 / 6787)
hyperten sion_1	14292 (68.748 %)	664 (69.602 %)	1.041 (0.904- 1.198, p=0.578)	0.0 400	0.0 72	0.5 56	0. 57 8	- 0.1 01	0.1 81	4.44% (664 / 14956)	95.56% (14292 / 14956)
coronary _disease _0	11288 (54.298 %)	599 (62.788 %)	-	-	-	-	-	-	-	5.039% (599 / 11887)	94.961% (11288 / 11887)

coronary _disease _1	9501 (45.702 %)	355 (37.212 %)	0.704 (0.616- 0.805, p=0.0)	- 0.3 508	0.0 68	- 5.1 28	0. 00 0	- 0.4 85	- 0.2 17	3.602% (355 / 9856)	96.398% (9501 / 9856)
atrial_fibr illation_0	18811 (90.485 %)	838 (87.841 %)	-	-	-	-	-	-	-	4.265% (838 / 19649)	95.735% (18811 / 19649)
atrial_fibr illation_1	1978 (9.515 %)	116 (12.159 %)	1.316 (1.078- 1.608, p=0.007)	0.2 749	0.1 02	2.6 99	0. 00 7	0.0 75	0.4 75	5.54% (116 / 2094)	94.46% (1978 / 2094)
hyperuric emia_0	18547 (89.215 %)	801 (83.962 %)	-	-	-	-	-	-	-	4.14% (801 / 19348)	95.86% (18547 / 19348)
hyperuric emia_1	2242 (10.785 %)	153 (16.038 %)	1.58 (1.322- 1.889, p=0.0)	0.4 575	0.0 91	5.0 27	0. 00 0	0.2 79	0.6 36	6.388% (153 / 2395)	93.612% (2242 / 2395)
hyperlipi daemia_ 0	16439 (79.075 %)	801 (83.962 %)	-	-	-	-	-	-	-	4.646% (801 / 17240)	95.354% (16439 / 17240)
hyperlipi daemia_ 1	4350 (20.925 %)	153 (16.038 %)	0.722 (0.605- 0.861, p=0.0)	- 0.3 259	0.0 90	- 3.6 27	0. 00 0	- 0.5 02	- 0.1 50	3.398% (153 / 4503)	96.602% (4350 / 4503)
hypoprot einemia_ 0	18479 (88.888 %)	774 (81.132 %)	-	-	-	-	-	-	-	4.02% (774 / 19253)	95.98% (18479 / 19253)
hypoprot einemia_ 1	2310 (11.112 %)	180 (18.868 %)	1.86 (1.573- 2.201, p=0.0)	0.6 208	0.0 86	7.2 48	0. 00 0	0.4 53	0.7 89	7.229% (180 / 2490)	92.771% (2310 / 2490)
cerebral _hernia_ 0	20626 (99.216 %)	934 (97.904 %)	-	-	-	-	-	-	-	4.332% (934 / 21560)	95.668% (20626 / 21560)
cerebral _hernia_ 1	163 (0.784 %)	20 (2.096 %)	2.71 (1.696- 4.332, p=0.0)	0.9 968	0.2 39	4.1 66	0. 00 0	0.5 28	1.4 66	10.929% (20 / 183)	89.071% (163 / 183)
hydrocep halus_0	20565 (98.923 %)	895 (93.816 %)	-	-	-	-	-	-	-	4.171% (895 / 21460)	95.829% (20565 / 21460)
hydrocep halus_1	224 (1.077 %)	59 (6.184 %)	6.052 (4.509- 8.125,	1.8 004	0.1 50	11. 98	0. 00	1.5 06	2.0 95	20.848% (59 / 283)	79.152% (224 / 283)

			p=0.0)			2	0				
frontal_lo be_0	19943 (95.931 %)	868 (90.985 %)	-	-	-	-	-	-	-	4.171% (868 / 20811)	95.829% (19943 / 20811)
frontal_lo be_1	846 (4.069 %)	86 (9.015 %)	2.336 (1.852- 2.945, p=0.0)	0.8 483	0.1 18	7.1 66	0. 00 0	0.6 16	1.0 80	9.227% (86 / 932)	90.773% (846 / 932)
parietal_l obe_0	20180 (97.071 %)	884 (92.662 %)	-	-	-	-	-	-	-	4.197% (884 / 21064)	95.803% (20180 / 21064)
parietal_l obe_1	609 (2.929 %)	70 (7.338 %)	2.624 (2.03- 3.391, p=0.0)	0.9 647	0.1 31	7.3 75	0. 00 0	0.7 08	1.2 21	10.309% (70 / 679)	89.691% (609 / 679)
temporal _lobe_0	20209 (97.21 %)	886 (92.872 %)	-	-	-	-	-	-	-	4.2% (886 / 21095)	95.8% (20209 / 21095)
temporal _lobe_1	580 (2.79%)	68 (7.128 %)	2.674 (2.063- 3.469, p=0.0)	0.9 836	0.1 33	7.4 13	0. 00 0	0.7 24	1.2 44	10.494% (68 / 648)	89.506% (580 / 648)
occipital _lobe_0	20422 (98.235 %)	919 (96.331 %)	-	-	-	-	-	-	-	4.306% (919 / 21341)	95.694% (20422 / 21341)
occipital _lobe_1	367 (1.765 %)	35 (3.669 %)	2.119 (1.489- 3.016, p=0.0)	0.7 511	0.1 80	4.1 70	0. 00 0	0.3 98	1.1 04	8.706% (35 / 402)	91.294% (367 / 402)
insular_l obe_0	20519 (98.701 %)	938 (98.323 %)	-	-	-	-	-	-	-	4.372% (938 / 21457)	95.628% (20519 / 21457)
insular_l obe_1	270 (1.299 %)	16 (1.677 %)	1.296 (0.78- 2.155, p=0.317)	0.2 595	0.2 59	1.0 00	0. 31 7	- 0.2 49	0.7 68	5.594% (16 / 286)	94.406% (270 / 286)
range_lo be_0	19559 (94.083 %)	830 (87.002 %)	-	-	-	-	-	-	-	4.071% (830 / 20389)	95.929% (19559 / 20389)
range_lo be_1	467 (2.246 %)	43 (4.507 %)	2.17 (1.576- 2.989, p=0.0)	0.7 746	0.1 63	4.7 45	0. 00 0	0.4 55	1.0 95	8.431% (43 / 510)	91.569% (467 / 510)
range_lo	329 (1.583	32 (3.354	2.292 (1.584-	0.8	0.1	4.3	0.	0.4	1.1	8.864% (32 /	91.136% (329 /

be_2	%)	%)	3.317, p=0.0)	294	89	99	00 0	60	99	361)	361)
range_lo be_3	224 (1.077 %)	31 (3.249 %)	3.261 (2.226- 4.778, p=0.0)	1.1 821	0.1 95	6.0 66	0. 00 0	0.8 00	1.5 64	12.157% (31 / 255)	87.843% (224 / 255)
range_lo be_4	175 (0.842 %)	15 (1.572 %)	2.02 (1.186- 3.438, p=0.01)	0.7 030	0.2 71	2.5 91	0. 01 0	0.1 71	1.2 35	7.895% (15 / 190)	92.105% (175 / 190)
range_lo be_5	35 (0.168 %)	3 (0.314 %)	2.02 (0.62- 6.58, p=0.243)	0.7 030	0.6 03	1.1 67	0. 24 3	- 0.4 78	1.8 84	7.895% (3 / 38)	92.105% (35 / 38)
basal_ga nglia_0	19869 (95.575 %)	893 (93.606 %)	-	-	-	-	-	-	-	4.301% (893 / 20762)	95.699% (19869 / 20762)
basal_ga nglia_1	920 (4.425 %)	61 (6.394 %)	1.475 (1.129- 1.927, p=0.004)	0.3 888	0.1 37	2.8 47	0. 00 4	0.1 21	0.6 56	6.218% (61 / 981)	93.782% (920 / 981)
brainste m_0	20532 (98.764 %)	938 (98.323 %)	-	-	-	-	-	-	-	4.369% (938 / 21470)	95.631% (20532 / 21470)
brainste m_1	257 (1.236 %)	16 (1.677 %)	1.363 (0.819- 2.268, p=0.234)	0.3 095	0.2 60	1.1 91	0. 23 4	- 0.2 00	0.8 19	5.861% (16 / 273)	94.139% (257 / 273)
epencep halon_0	20362 (97.946 %)	934 (97.904 %)	-	-	-	-	-	-	-	4.386% (934 / 21296)	95.614% (20362 / 21296)
epencep halon_1	427 (2.054 %)	20 (2.096 %)	1.021 (0.649- 1.606, p=0.928)	0.0 209	0.2 31	0.0 90	0. 92 8	- 0.4 32	0.4 74	4.474% (20 / 447)	95.526% (427 / 447)
paravent ricular_0	19786 (95.175 %)	899 (94.235 %)	-	-	-	-	-	-	-	4.346% (899 / 20685)	95.654% (19786 / 20685)
paravent ricular_1	1003 (4.825 %)	55 (5.765 %)	1.207 (0.912- 1.597, p=0.187)	0.1 880	0.1 43	1.3 18	0. 18 7	- 0.0 92	0.4 68	5.198% (55 / 1058)	94.802% (1003 / 1058)
centrum _semiov ale_0	20207 (97.2%)	922 (96.646 %)	-	-	-	-	-	-	-	4.364% (922 / 21129)	95.636% (20207 / 21129)

centrum _semiov ale_1	582 (2.8%)	32 (3.354 %)	1.205 (0.839-1.73, p=0.313)	0.1 865	0.1 85	1.0 10	0. 31 3	- 0.1 75	0.5 48	5.212% (32 / 614)	94.788% (582 / 614)
thalamus _0	20565 (98.923 %)	937 (98.218 %)	-	-	-	-	-	-	-	4.358% (937 / 21502)	95.642% (20565 / 21502)
thalamus _1	224 (1.077 %)	17 (1.782 %)	1.666 (1.013-2.74, p=0.044)	0.5 102	0.2 54	2.0 11	0. 04 4	0.0 13	1.0 08	7.054% (17 / 241)	92.946% (224 / 241)
aca_0	20524 (98.725 %)	941 (98.637 %)		-	-	-	-	-	-	4.384% (941 / 21465)	95.616% (20524 / 21465)
aca_1	265 (1.275 %)	13 (1.363 %)	1.07 (0.611- 1.874, p=0.813)	0.0 676	0.2 86	0.2 36	0. 81 3	- 0.4 93	0.6 28	4.676% (13 / 278)	95.324% (265 / 278)
mca_0	19998 (96.195 %)	912 (95.597 %)	-	-	-	-	-	-	-	4.362% (912 / 20910)	95.638% (19998 / 20910)
mca_1	791 (3.805 %)	42 (4.403 %)	1.164 (0.848- 1.598, p=0.348)	0.1 521	0.1 62	0.9 39	0. 34 8	- 0.1 65	0.4 69	5.042% (42 / 833)	94.958% (791 / 833)
pca_0	20729 (99.711 %)	952 (99.79 %)	-	-	-	-	-	-	-	4.391% (952 / 21681)	95.609% (20729 / 21681)
pca_1	60 (0.289 %)	2 (0.21%)	0.726 (0.177- 2.974, p=0.656)	- 0.3 205	0.7 20	- 0.4 45	0. 65 6	- 1.7 31	1.0 90	3.226% (2 / 62)	96.774% (60 / 62)
va_0	20159 (96.97 %)	927 (97.17 %)		-	-	-	-	-	-	4.396% (927 / 21086)	95.604% (20159 / 21086)
va_1	630 (3.03%)	27 (2.83%)	0.932 (0.631- 1.377, p=0.724)	- 0.0 704	0.1 99	- 0.3 53	0. 72 4	- 0.4 61	0.3 20	4.11% (27 / 657)	95.89% (630 / 657)
ba_0	20605 (99.115 %)	945 (99.057 %)	-	-	-	-	-	-	-	4.385% (945 / 21550)	95.615% (20605 / 21550)
ba_1	184 (0.885 %)	9 (0.943 %)	1.067 (0.544-2.09, p=0.851)	0.0 644	0.3 43	0.1 88	0. 85	- 0.6 08	0.7 37	4.663% (9 / 193)	95.337% (184 / 193)

1

gender_ 0	10407 (50.06 %)	372 (38.994 %)	-	-	-	-	-	-	-	3.451% (372 / 10779)	96.549% (10407 / 10779)
gender_ 1	10382 (49.94 %)	582 (61.006 %)	1.568 (1.373- 1.791, p=0.0)	0.4 500	0.0 68	6.6 35	0. 00 0	0.3 17	0.5 83	5.308% (582 / 10964)	94.692% (10382 / 10964)
cca_plaq ue_0	16100 (77.445 %)	751 (78.721 %)	-	-	-	-	-	-	-	4.457% (751 / 16851)	95.543% (16100 / 16851)
cca_plaq ue_1	4689 (22.555 %)	203 (21.279 %)	0.928 (0.792- 1.088, p=0.356)	- 0.0 746	0.0 81	- 0.9 23	0. 35 6	- 0.2 33	0.0 84	4.15% (203 / 4892)	95.85% (4689 / 4892)
ica_plaq ue_0	19392 (93.28 %)	878 (92.034 %)	-	-	-	-	-	-	-	4.332% (878 / 20270)	95.668% (19392 / 20270)
ica_plaq ue_1	1397 (6.72%)	76 (7.966 %)	1.202 (0.945- 1.528, p=0.135)	0.1 836	0.1 23	1.4 96	0. 13 5	- 0.0 57	0.4 24	5.16% (76 / 1473)	94.84% (1397 / 1473)
eca_plaq ue_0	20591 (99.048 %)	942 (98.742 %)	-	-	-	-	-	-	-	4.375% (942 / 21533)	95.625% (20591 / 21533)
eca_plaq ue_1	198 (0.952 %)	12 (1.258 %)	1.325 (0.737- 2.382, p=0.347)	0.2 812	0.2 99	0.9 40	0. 34 7	- 0.3 05	0.8 68	5.714% (12 / 210)	94.286% (198 / 210)
subcorte x_lobe_0	18454 (88.768 %)	814 (85.325 %)	-	-	-	-	-	-	-	4.225% (814 / 19268)	95.775% (18454 / 19268)
subcorte x_lobe_1	2335 (11.232 %)	140 (14.675 %)	1.359 (1.131- 1.634, p=0.001)	0.3 070	0.0 94	3.2 62	0. 00 1	0.1 23	0.4 91	5.657% (140 / 2475)	94.343% (2335 / 2475)

Table 2.Univariable logistic regression results

Footuro	0 (N=2079	1	OR	Coef	Std.Er	_	P> z	[0.02	0.97
reature	(IN-2078 9)	(N=954)	(multivariable)		r.	Z	I	5	5]

tg	1.536 ± 0.433	1.662 ± 0.484	2.458 (2.069- 2.92, p=0.0)	0.89 9	0.088	10.23	0	0.727	1.07 1
rbc	4.304 ± 0.324	4.408 ± 0.274	4.731 (3.274- 6.837, p=0.0)	1.55 4	0.188	8.275	0	1.186	1.92 2
age	66.806 ± 12.597	65.335 ± 13.909	1.012 (1.004- 1.021, p=0.003)	0.01 2	0.004	2.971	0.00 3	0.004	0.02 1
ast	26.05 ± 12.823	38.25 ± 18.205	1.048 (1.04- 1.055, p=0.0)	0.04 6	0.004	12.41 3	0	0.039	0.05 4
plt	190.132 ± 26.424	180.251 ± 36.939	0.977 (0.973- 0.98, p=0.0)	0.02 4	0.002	- 13.37 5	0	- 0.027	-0.02
alt	24.193 ± 10.108	26.827 ± 10.349	0.953 (0.942- 0.964, p=0.0)	0.04 8	0.006	8.177	0	0.059	_ 0.03 6
ima	75.458 ± 12.891	81.624 ± 8.559	1.006 (1.001- 1.012, p=0.014)	0.00 6	0.003	2.453	0.01 4	0.001	0.01 2
ldh	215.357 ± 75.036	296.455 ± 111.282	0.984 (0.982- 0.987, p=0.0)	0.01 6	0.001	- 12.99 2	0	- 0.018	- 0.01 4
tt	16.432 ± 0.615	16.636 ± 0.809	1.13 (1.009- 1.265, p=0.034)	0.12 2	0.058	2.116	0.03 4	0.009	0.23 5
crp	15.314 ± 18.865	55.681 ± 48.823	1.032 (1.028- 1.036, p=0.0)	0.03 1	0.002	15.58 5	0	0.027	0.03 5
wbc	8.316 ± 1.286	11.79 ± 3.084	2.091 (1.985- 2.204, p=0.0)	0.73 8	0.027	27.58 3	0	0.685	0.79

ck	195.007 ± 273.212	1029.59 4 ± 872.8	1.001 (1.001- 1.001, p=0.0)	0.00 1	0	7.86	0	0.001	0.00 1
subcortex_lobe_ 0	18454 (88.768 %)	814 (85.325 %)	-	-	-	-	-	-	-
subcortex_lobe_ 1	2335 (11.232 %)	140 (14.675 %)	1.188 (0.827- 1.707 ,p=0.35 2)	0.17 2	0.185	0.93	0.35 2	- 0.191	0.53 5
frontal_lobe_0	19943 (95.931 %)	868 (90.985 %)	-	-	-	-	-	-	-
frontal_lobe_1	846 (4.069%)	86 (9.015%)	4.577 (1.381- 15.17 ,p=0.01 3)	1.52 1	0.611	2.488	0.01 3	0.323	2.71 9
cerebral_hernia_ 0	20626 (99.216 %)	934 (97.904 %)	-	-	-	-	-	-	-
cerebral_hernia_ 1	163 (0.784%)	20 (2.096%)	0.846 (0.387- 1.85 ,p=0.676)	0.16 7	0.399	0.418	0.67 6	0.949	0.61 5
thalamus_0	20565 (98.923 %)	937 (98.218 %)	-	-	-	-	-	-	-
thalamus_1	224 (1.077%)	17 (1.782%)	0.669 (0.327- 1.373 ,p=0.27 3)	0.40 1	0.366	1.095	0.27 3	- 1.119	0.31 7
occipital_lobe_0	20422 (98.235 %)	919 (96.331 %)	-	-	-	-	-	-	-

occipital_lobe_1	367 (1.765%)	35 (3.669%)	2.172 (0.741- 6.368 ,p=0.15 7)	0.77 6	0.549	1.414	0.15 7	-0.3	1.85 1
coronary_diseas e_0	11288 (54.298 %)	599 (62.788 %)	-	-	-	-	-	-	-
coronary_diseas e_1	9501 (45.702 %)	355 (37.212 %)	1.408 (1.151- 1.724 ,p=0.00 1)	0.34 2	0.103	3.322	0.00 1	0.14	0.54 5
hypoproteinemia _0	18479 (88.888 %)	774 (81.132 %)	-	-	-	-	-	-	-
hypoproteinemia _1	2310 (11.112 %)	180 (18.868 %)	1.183 (0.9- 1.554 ,p=0.22 8)	0.16 8	0.139	1.206	0.22 8	- 0.105	0.44 1
parietal_lobe_0	20180 (97.071 %)	884 (92.662 %)	-	-	-	-	-	-	-
parietal_lobe_1	609 (2.929%)	70 (7.338%)	6.939 (2.253- 21.375 ,p=0.0 01)	1.93 7	0.574	3.375	0.00 1	0.812	3.06 2
hyperuricemia_0	18547 (89.215 %)	801 (83.962 %)	-	-	-	-	-	-	-
hyperuricemia_1	2242 (10.785 %)	153 (16.038 %)	0.938 (0.691- 1.275 ,p=0.68 4)	- 0.06 4	0.156	- 0.407	0.68 4	-0.37	0.24 3
temporal_lobe_0	20209 (97.21%)	886 (92.872 %)	-	-	-	-	-	-	-

temporal_lobe_1	580 (2.79%)	68 (7.128%)	5.242 (1.548- 17.752 ,p=0.0 08)	1.65 7	0.622	2.662	0.00 8	0.437	2.87 6
range_lobe_0	19559 (94.083 %)	830 (87.002 %)	-	-	-	-	-	-	-
range_lobe_1	467 (2.246%)	43 (4.507%)	0.359 (0.111- 1.159 ,p=0.08 7)	1.02 5	0.598	1.713	0.08 7	- 2.197	0.14 7
range_lobe_2	329 (1.583%)	32 (3.354%)	0.084 (0.01- 0.703 ,p=0.02 2)	2.47 9	1.085	- 2.285	0.02 2	- 4.605	- 0.35 2
range_lobe_3	224 (1.077%)	31 (3.249%)	0.011 (0.0- 0.231 ,p=0.00 4)	4.54 2	1.569	- 2.895	0.00 4	- 7.617	- 1.46 7
range_lobe_4	175 (0.842%)	15 (1.572%)	0.001 (0.0- 0.057 ,p=0.00 1)	6.66 6	1.943	-3.43	0.00 1	- 10.47 5	- 2.85 7
range_lobe_5	35 (0.168%)	3 (0.314%)	0.001 (0.0- 0.115 ,p=0.00 4)	6.58 6	2.259	- 2.915	0.00 4	- 11.01 4	- 2.15 9
hydrocephalus_ 0	20565 (98.923 %)	895 (93.816 %)	-	-	-	-	-	-	-
hydrocephalus_ 1	224 (1.077%)	59 (6.184%)	3.251 (1.939- 5.451 ,p=0.0)	1.17 9	0.264	4.471	0	0.662	1.69 6
gender_0	10407 (50.06%)	372 (38.994 %)	-	-	-	-	-	-	-

gender_1	10382 (49.94%)	582 (61.006 %)	0.572 (0.454- 0.72 ,p=0.0)	0.55 8	0.117	4.753	0	0.789	- 0.32 8
uremia_0	20618 (99.177 %)	934 (97.904 %)	-	-	-	-	-	-	-
uremia_1	171 (0.823%)	20 (2.096%)	1.979 (1.098- 3.564 ,p=0.02 3)	0.68 2	0.3	2.273	0.02 3	0.094	1.27 1
atrial_fibrillation_ 0	18811 (90.485 %)	838 (87.841 %)	-	-	-	-	-	-	-
atrial_fibrillation_ 1	1978 (9.515%)	116 (12.159 %)	1.446 (1.087- 1.923 ,p=0.01 1)	0.36 9	0.145	2.534	0.01 1	0.084	0.65 4
basal_ganglia_0	19869 (95.575 %)	893 (93.606 %)	-	-	-	-	-	-	-
basal_ganglia_1	920 (4.425%)	61 (6.394%)	1.024 (0.642- 1.633 ,p=0.92 1)	0.02 4	0.238	0.099	0.92 1	0.443	0.49
dvt_0	19534 (93.963 %)	847 (88.784 %)	-	-	-	-	-	-	-
dvt_1	1255 (6.037%)	107 (11.216 %)	1.254 (0.922- 1.706 ,p=0.14 9)	0.22 7	0.157	1.443	0.14 9	0.081	0.53 4
hyperlipidaemia_ 0	16439 (79.075 %)	801 (83.962 %)	-	-	-	-	-	-	-

hyperlipidaemia_ 1	4350 (20.925 %)	153 (16.038 %)	0.825 (0.646- 1.052 ,p=0.12 1)	_ 0.19 3	0.124	1.552	0.12 1	0.437	0.05 1
fatty_liver_0	16655 (80.114 %)	812 (85.115 %)	-	-	-	-	-	-	-
fatty_liver_1	4134 (19.886 %)	142 (14.885 %)	0.759 (0.59- 0.978 ,p=0.03 3)	- 0.27 5	0.129	2.135	0.03 3	0.528	0.02 3

T 1 1 1	1 1 1	1	111			1.
Ianie	< MIII	Ifivaria	niair	N OI STIC	regression	reculte
Table	Julu	iti vai ia	DIC IC	gistic	regression	ICSUID

Model	AUC	Accuracy	Sensitivity/Recall	Specificity	F1-score	PPV/precision
LR	0.967 0.973	0.928 0.927	0.920 0.929	0.928 0.927	0.530 0.524	0.373 0.365
NB	0.903 0.909	0.938 0.936	0.634 0.662	0.952 0.949	0.474 0.472	0.378 0.367
DT	0.997 0.906	0.993 0.970	1.000 0.836	0.993 0.976	0.930 0.706	0.870 0.610
GB	0.998 0.992	0.987 0.980	0.976 0.900	0.988 0.983	0.871 0.794	0.786 0.711
RF	1.000 0.996	0.997 0.989	1.000 0.883	0.997 0.994	0.967 0.873	0.936 0.864
MLP	0.996 0.984	0.977 0.972	0.975 0.932	0.977 0.974	0.790 0.744	0.664 0.619
XGB	1.000 0.996	0.996 0.988	1.000 0.897	0.996 0.992	0.961 0.867	0.926 0.840
LGBM	1.000 0.996	0.997 0.989	1.000 0.886	0.997 0.993	0.970 0.869	0.941 0.853
KNN	0.997 0.955	0.965 0.955	0.999 0.890	0.964 0.958	0.717 0.631	0.560 0.489

Table 4.The AUC, Accuracy, Sensitivity, Specificity, F1-score, positive predictive value (PPV) and negative predictive value (NPV) of ML models of train|test groups